Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure
Open Access
- 8 December 2021
- journal article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 26 (12), 4800
- https://doi.org/10.15829/1560-4071-2021-4800
Abstract
Aim. To assess the effect of therapy with sodium glucose co-transporter type 2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction (CHrEF) on the state cardiovascular mortality target indicators.Material and methods. All adult Russian patients with NYHA class II-IV HFrEF (left ventricular ejection fraction ≤40%) were considered as the target population. The characteristics of patients in the study corresponded to those in the Russian Hospital HF Registry (RUS-HFR). The study suggests that the use of dapagliflozin in addition to standard therapy will be expanded by 10% of the patient population annually in 2022-24. Cardiovascular mortality modeling was performed based on the extrapolation of DAPA-HF study result. The number of deaths that can be prevented was calculated when using dapagliflozin in addition to standard therapy. Further, the contribution of prevented deaths with dapagliflozin therapy to the achievement of federal and regional cardiovascular mortality target indicators (1, 2 and 3 years) was calculated.Results. The use of dapagliflozin in addition to standard therapy for patients with NYHA class II-IV CHrEF with the expansion of dapagliflozin therapy by 10% of the patient population annually will additionally prevent 1729 cardiovascular death in the first year. This will ensure the implementation of cardiovascular mortality target indicators in Russia in 2022 by 11,8%. In the second year, 3769 cardiovascular deaths will be prevented, which will ensure the implementation of target indicators in 2023 by 17,2%. In the third year, 5465 cardiovascular deaths prevented, which will ensure the implementation of implementation of target indicators in 2024 by 18,7%.Conclusion. The use of dapagliflozin in addition to standard therapy for patients with NYHA class II-IV CHrEF will ensure the implementation of implementation of target indicators in 2024 by 18,7%.Keywords
This publication has 11 references indexed in Scilit:
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2021
- Coronavirus disease 2019: features of comprehensive cardiac and pulmonary rehabilitationRussian Journal of Cardiology, 2021
- 2020 Clinical practice guidelines for Chronic heart failureRussian Journal of Cardiology, 2020
- Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseasesRussian Journal of Cardiology, 2020
- Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart FailureJAMA Cardiology, 2020
- Cardiovascular risk management system: prerequisites for developing, organization principles, target groupsRussian Journal of Cardiology, 2019
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionThe New England Journal of Medicine, 2019
- Prescription drug coverage in high cardiovascular risk patients as an important part of the national goals achievementVestnik Roszdravnadzora, 2019
- Characteristics and treatment of hospitalized patients with CHFKardiologiia, 2017
- CHRONIC HEART FAILURE IN RUSSIAN FEDERATION: WHAT DO WE KNOW AND WHAT TO DORussian Journal of Cardiology, 2016